AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables

Quarterly Annual

Latest, Q2 2026

1,804

Period ended Jun 30, 2026

Change on a year earlier

-16.1%

2,150 in Q2 2025

History

42 quarters

Since Q1 2016

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	1,804	-16.1%	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	2,193	+6.6%	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	2,059	+6.5%	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	2,134	+10.1%	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	2,150	+10.8%	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	2,057	+11.5%	Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024	Dec 31, 2024	1,933	+20.4%	Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024	Sep 30, 2024	1,938	+24.7%	Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024	Jun 30, 2024	1,940	+28.9%	Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024	Mar 31, 2024	1,845	+42.0%	Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023	Dec 31, 2023	1,606	+36.4%	Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023	Sep 30, 2023	1,554	+41.1%	Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023	Jun 30, 2023	1,505	+36.4%	Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023	Mar 31, 2023	1,299	+29.9%	Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022	Dec 31, 2022	1,177	+38.8%	Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022	Sep 30, 2022	1,101	+38.3%	Form 6-K FY2022Q3 Earnings Release ↗
Q2 2022	Jun 30, 2022	1,103	+50.7%	Form 6-K FY2022Q2 Earnings Release ↗
Q1 2022	Mar 31, 2022	1,000	+60.3%	Form 6-K FY2022Q1 Earnings Release ↗
Q4 2021	Dec 31, 2021	848	+44.7%	Form 6-K FY2021Q4 Earnings Release ↗
Q3 2021	Sep 30, 2021	796	+51.6%	Form 6-K FY2021Q3 Earnings Release ↗
Q2 2021	Jun 30, 2021	732	+65.2%	Form 6-K FY2021Q2 Earnings Release ↗
Q1 2021	Mar 31, 2021	624	+54.1%	Form 6-K FY2021Q1 Earnings Release ↗
Q4 2020	Dec 31, 2020	586	+39.9%	Form 6-K FY2020Q4 Earnings Release ↗
Q3 2020	Sep 30, 2020	525	+31.9%	Form 6-K (filed 2021-07-30) ↗
Q2 2020	Jun 30, 2020	443	+17.5%	Form 6-K/A (filed 2020-07-31) ↗
Q1 2020	Mar 31, 2020	405	+16.0%	Form 6-K/A (filed 2020-07-31) ↗
Q4 2019	Dec 31, 2019	419	+5.5%	Form 6-K/A (filed 2020-07-31) ↗
Q3 2019	Sep 30, 2019	398	+12.1%	Form 6-K/A (filed 2020-07-31) ↗
Q2 2019	Jun 30, 2019	377	+10.9%	Form 6-K (filed 2019-07-25) ↗
Q1 2019	Mar 31, 2019	349	+16.7%	Form 6-K (filed 2019-07-25) ↗
Q4 2018	Dec 31, 2018	397	+19.6%	Form 6-K (filed 2019-07-25) ↗
Q3 2018	Sep 30, 2018	355	+24.6%	Form 6-K (filed 2019-07-25) ↗
Q2 2018	Jun 30, 2018	340	+36.0%	Form 6-K (filed 2018-07-26) ↗
Q1 2018	Mar 31, 2018	299	+44.4%	Form 6-K (filed 2018-07-26) ↗
Q4 2017	Dec 31, 2017	332	+38.9%	Form 6-K (filed 2018-07-26) ↗
Q3 2017	Sep 30, 2017	285	+29.5%	Form 6-K (filed 2018-07-26) ↗
Q2 2017	Jun 30, 2017	250	+18.5%	Form 6-K (filed 2018-07-26) ↗
Q1 2017	Mar 31, 2017	207	+25.5%	Form 6-K (filed 2018-07-26) ↗
Q4 2016	Dec 31, 2016	239	–	Form 6-K (filed 2018-07-26) ↗
Q3 2016	Sep 30, 2016	220	–	Form 6-K (filed 2018-07-26) ↗
Q2 2016	Jun 30, 2016	211	–	Form 6-K (filed 2018-07-26) ↗
Q1 2016	Mar 31, 2016	165	–	Form 6-K (filed 2018-07-26) ↗

Breakdown

What makes up farxiga / forxiga (dapagliflozin) — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_farxiga_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.